Panacos Pharmaceuticals, Inc.

Watertown, MA 02472

SBIR Award Summary

Total Number of Awards 9
Total Value of Awards $2.97MM
First Award Date 06/01/96
Most Recent Award Date 04/01/05

Key Personnel

Last Name Name Awards Contact
Horowitz Bernard Horowitz 1
Heldman Eliahu Heldman 1
Wild Carl T. Wild 1
Allaway Graham P Allaway 2
Salzwedel Karl D. Salzwedel 1
Chapman John R Chapman 3

9 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-01-52
Budget: 04/01/05 - 03/31/06

Description (provided by applicant): There is a pressing need for new drugs to treat HIV infection by virus strains that are resistant to the approved reverse transcriptase and protease inhibitors. Panacos Pharmaceuticals' approach to overcoming drug resistance involves identifying HIV drug candidates with novel mechanisms of action. In colla...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 01/15/05 - 01/14/06

DESCRIPTION (provided by applicant): In the United States, there are approximately 14 million units of red cell concentrates transfused annually. To address the health risks of bloodborne pathogens, pathogen reduction technologies are being developed for cellular blood products. To inactivate microbes in blood, a microbiocidal compound designate...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-01-52
Budget: 08/01/04 - 07/31/05

DESCRIPTION (provided by applicant): While progress has been made in the discovery and development of drugs to treat HIV infection, significant problems remain, including the development of drug resistance. In order to expand treatment options and reduce the rate of resistance development, drugs that target viral replication at points other tha...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/15/04 - 05/31/05

DESCRIPTION (provided by investigator): Respiratory Syncytial Virus (RSV) is a major disease-causing agent, resulting in severe lower respiratory tract infection in infants, immunocompromised patients, and the elderly. In the U.S. alone it is estimated that RSV is responsible for 125,000 pediatric hospitalizations annually with a mortality rate ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-01-52
Budget: 04/01/04 - 03/31/05

Description (provided by applicant): There is a pressing need for new drugs to treat HIV infection by virus strains that are resistant to the approved reverse transcriptase and protease inhibitors. Panacos Pharmaceuticals' approach to overcoming drug resistance involves identifying HIV drug candidates with novel mechanisms of action. In colla...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 01/15/04 - 01/14/05

DESCRIPTION (provided by applicant): In the United States, there are approximately 14 million units of red cell concentrates transfused annually. To address the health risks of bloodborne pathogens, pathogen reduction technologies are being developed for cellular blood products. To inactivate microbes in blood, a microbiocidal compound designate...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/15/03 - 01/14/04

DESCRIPTION (provided by applicant): In the United States, there are approximately 14 million units of red cell concentrates transfused annually. To address the health risks of bloodborne pathogens, pathogen reduction technologies are being developed for cellular blood products. To inactivate microbes in blood, a microbiocidal compound designate...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/98 - 02/28/99

Our objective is to develop an albumin solder as a complete or partial substitute for sutures or staples during surgery. The solder is applied on the wound and welding is achieved by laser irradiation. The welding requires heat that may cause tissue necrosis. The investigators propose to produce a "low tempe...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/96 - 11/30/96